Psoriasis and psoriatic arthritis are complex autoimmune diseases affecting ~2-3% of world population. With the advancement in translational research, the pathogenesis of these diseases are better known now compared to a decade ago. New therapeutic targets have been identified, and subsequently more effective therapies are now available for these patients. With these new therapies, psoriatic diseases are much better controlled, and quality of life has improved greatly. Most of these newer therapies are targeting the immune system and their molecular signaling pathways. In this Research Topic, we are planning to gather articles on new therapeutic strategies for psoriatic disease, their limitations and future directions.
The goal of this Research Topic is to enrich our knowledge in the area of therapeutic advancement of psoriatic disease which includes FDA approved medications in the last 5 years, medications in different phases of clinical trials, the mechanism of action of these newer therapies, safety profile and limitations. Here, we invite authors to submit manuscripts that broaden our knowledge of therapeutic advancements in psoriatic diseases in the form of either original articles, reviews, or mini-reviews. Specifically, we are interested in the following themes:
• Novel therapeutic target(s) for psoriatic disease
• Recently (last 5 years) approved therapies for psoriatic disease
• Biosimilars - role in psoriatic disease
• Safety profile of newer therapies
• Economic impact of newer therapies on health system
• Newer mode of drug-delivery system in psoriatic disease
• Therapeutic prospect of small molecules in psoriatic disease
• Therapeutic guidelines to combine newer therapies with conventional therapy in psoriatic disease
• Plant derived compounds in psoriatic disease
• Pathophysiology and therapies in the future of psoriasis and psoriatic arthritis treatment
Psoriasis and psoriatic arthritis are complex autoimmune diseases affecting ~2-3% of world population. With the advancement in translational research, the pathogenesis of these diseases are better known now compared to a decade ago. New therapeutic targets have been identified, and subsequently more effective therapies are now available for these patients. With these new therapies, psoriatic diseases are much better controlled, and quality of life has improved greatly. Most of these newer therapies are targeting the immune system and their molecular signaling pathways. In this Research Topic, we are planning to gather articles on new therapeutic strategies for psoriatic disease, their limitations and future directions.
The goal of this Research Topic is to enrich our knowledge in the area of therapeutic advancement of psoriatic disease which includes FDA approved medications in the last 5 years, medications in different phases of clinical trials, the mechanism of action of these newer therapies, safety profile and limitations. Here, we invite authors to submit manuscripts that broaden our knowledge of therapeutic advancements in psoriatic diseases in the form of either original articles, reviews, or mini-reviews. Specifically, we are interested in the following themes:
• Novel therapeutic target(s) for psoriatic disease
• Recently (last 5 years) approved therapies for psoriatic disease
• Biosimilars - role in psoriatic disease
• Safety profile of newer therapies
• Economic impact of newer therapies on health system
• Newer mode of drug-delivery system in psoriatic disease
• Therapeutic prospect of small molecules in psoriatic disease
• Therapeutic guidelines to combine newer therapies with conventional therapy in psoriatic disease
• Plant derived compounds in psoriatic disease
• Pathophysiology and therapies in the future of psoriasis and psoriatic arthritis treatment
